Shares of Arena Pharmaceuticals ARNA decreased 19.4% in after-market trading after the company reported Q3 results.
Earnings per share fell 15.75% over the past year to ($1.69), which beat the estimate of ($1.87).
Revenue of $20,000 decreased by 98.52% from the same period last year, which missed the estimate of $1,230,000.
Arena Pharmaceuticals hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
Details Of The Call
Date: Nov 09, 2020
Time: 04:30 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/2hjtyigg
Recent Stock Performance
52-week high: $90.19
52-week low: $32.95
Price action over last quarter: Up 8.00%
Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company's pipeline contains drugs targeting autoimmune diseases, vascular diseases, thrombotic diseases, dementia-associated psychosis, nervous system issues, and pain.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.